Cost-utility analysis of combination therapy of type 2 diabetes mellitus in Ukraine

Joint Event on 3rd World Congress on NATURAL PRODUCTS CHEMISTRY AND RESEARCH & 12th WORLD PHARMA CONGRESS
October 16-18, 2017 Budapest, Hungary

Ivko T and Germanyuk T

National Pirogov Memorial Medical University, Ukraine

Posters & Accepted Abstracts: Am J Ethnomed

DOI: 10.21767/2348-9502-C1-003

Abstract

Background: Type 2 diabetes mellitus (T2DM) is a serious medical and social problem. T2DM has a severe and progressive course, complications, metabolic disorders and high disability, which significantly reduce the quality of life of patients.

Objectives: To evaluate the cost-utility of the therapy regimes with Metformin+Glibenclamide compared with Metformin+Glimepiride and Metformin+Gliclazide. Methods: The decision tree model was used to estimate the incremental costs and quality-adjusted life expectancy in patients with T2DM by health economics methods. 150 questionnaires to determine the quality of life of patients with T2DM were used. These patients were treated in the endocrinology clinics of Podolsky region of Ukraine in 2011-2013. The quality of life of patients was determined by visual analogue scale adapted European questionnaire of quality of life EuroQol-5D. The patients were examined on the following parameters: age, duration of T2DM, body mass index, the average fasting plasma glucose, cost-utility ratios. It has been found that patients with Metformin+Glibenclamide regime were significantly older, with the largest T2DM duration, with the highest body mass index and highest levels of fasting plasma glucose, cheapest costutility ratio. In comparing patients with Metformin+Gliclazide and Metformin+Glimepiride regimes it was found no other significant differences (├?┬?>0.05). Calculations take into account the direct costs only. Treatment costs were estimated on the basis of average wholesale government drug price list as at 12.06.2014. To determine the stability of results sensitivity analysis was performed.

Results: The decision tree model predicted that Metformin+Glibenclamide therapy regime has cheapest cost-utility ratio; when compared Metformin+Glibenclamide therapy regime with Metformin+Glimepiride an incremental cost-utility ratio was 60 UAH and while gaining 0.11±0.04 quality-adjusted life-years (QALYs). Compared Metformin+Glibenclamide therapy regime with Metformin+Gliclazide an incremental cost-utility ratio was 318 UAH and while gaining 0.14±0.01QALYs.

Conclusions: Scheme of combined therapy Metformin+Glibenclamide has cost-utility advantages in comparison with other combined schemes of T2DM.

Biography

E-mail: [email protected]